In 2024, the number of ****** cancer cases among women in Japan reached approximately ******, which made it the most common type of cancer for women. The estimated total number of cancer cases for Japanese women in that year amounted to almost 421,000. Most common types of cancer in Japan Following breast cancer, colon and rectum, lung, as well as stomach were the most frequently diagnosed cancer sites among women in Japan. In contrast, prostate cancer was the most frequently diagnosed cancer among men, followed by stomach, colon and rectum, and lung cancer.Different types of cancer rank among the most common causes of death among Japanese people. In terms of cancer-related mortality among women in Japan, lung cancer claimed the highest number of lives in recent years, followed by pancreatic cancer.  Prevention and treatment of breast cancer In recent years, colon, cervix, lung, breast, and stomach were the most common cancer sites for screening in Japan. This was supported by a survey from 2023, in which over 36 percent of Japanese women stated that they had a cancer screening in the past two years.More attention has been given to breast cancer treatment as the incidence of breast cancer in Japan has grown throughout the past decades. Consequently, the number of general hospitals equipped with breast surgery departments increased as well.The early detection of breast cancer is crucial to increase the chance of survival. The primary approach to breast cancer treatment involves surgical removal of the cancer, though preoperative drug therapy may be administered based on the cancer's condition.

In 2023, the crude mortality rate for cancer in Japan accounted for a record-high of ***** per 100,000 people. The rate has been showing a persistent upward trajectory since 1995. Cancer has been the leading cause of death in Japan for ** consecutive years since 1981.

BackgroundBetter information on lung cancer occurrence in lifelong nonsmokers is needed to understand gender and racial disparities and to examine how factors other than active smoking influence risk in different time periods and geographic regions. Methods and FindingsWe pooled information on lung cancer incidence and/or death rates among self-reported never-smokers from 13 large cohort studies, representing over 630,000 and 1.8 million persons for incidence and mortality, respectively. We also abstracted population-based data for women from 22 cancer registries and ten countries in time periods and geographic regions where few women smoked. Our main findings were: (1) Men had higher death rates from lung cancer than women in all age and racial groups studied; (2) male and female incidence rates were similar when standardized across all ages 40+ y, albeit with some variation by age; (3) African Americans and Asians living in Korea and Japan (but not in the US) had higher death rates from lung cancer than individuals of European descent; (4) no temporal trends were seen when comparing incidence and death rates among US women age 40–69 y during the 1930s to contemporary populations where few women smoke, or in temporal comparisons of never-smokers in two large American Cancer Society cohorts from 1959 to 2004; and (5) lung cancer incidence rates were higher and more variable among women in East Asia than in other geographic areas with low female smoking. ConclusionsThese comprehensive analyses support claims that the death rate from lung cancer among never-smokers is higher in men than in women, and in African Americans and Asians residing in Asia than in individuals of European descent, but contradict assertions that risk is increasing or that women have a higher incidence rate than men. Further research is needed on the high and variable lung cancer rates among women in Pacific Rim countries.

S1 File. Community SES information. S1 Fig. Scatterplot of the relationship between community land price (A), neighborhood income (B), education level (C), and employment rate (D), with stomach cancer morbidity and mortality for men and women in Kanagawa, Japan, 2000–2015. Each plot shows data per year and community. 1$ = 133 Japanese Yen, the rate on March 20, 2023. S2 Fig. Scatterplot of the relationship between community land price (A), neighborhood income (B), education level (C), and employment rate (D), with colorectal cancer morbidity and mortality for men and women in Kanagawa, Japan, 2000–2015. Each plot shows data per year and community. 1$ = 133 Japanese Yen, the rate on March 20, 2023. S3 Fig. Scatterplot of the relationship between community land price (A), neighborhood income (B), education level (C), and employment rate (D), with liver cancer morbidity and mortality for men and women in Kanagawa, Japan, 2000–2015. Each plot shows data per year and community. 1$ = 133 Japanese Yen, the rate on March 20, 2023. S4 Fig. Scatterplot of the relationship between community land price (A), neighborhood income (B), education level (C), and employment rate (D), with breast cancer morbidity and mortality for women in Kanagawa, Japan, 2000–2015. Each plot shows data per year and community. 1$ = 133 Japanese Yen, the rate on March 20, 2023. S1 Table. Correlation coefficients of the aging rate, screening rate, and community SES indicators in Kanagawa, Japan, 2000–2015. S2 Table. VIF of the Poisson regression using community SES indicator, aging rate, and year as explanatory variables. S3 Table. VIF of the Poisson regression using community SES indicator, aging rate, year, and municipality code as explanatory variables. S4 Table. Multilevel analysis by the year for cancer morbidity in Kanagawa, Japan, 2000–2015. S5 Table. Multilevel analysis by the year for cancer mortality in Kanagawa, Japan, 2000–2015. S6 Table. Multilevel analysis by the municipality code for cancer morbidity in Kanagawa, Japan, 2000–2015. S7 Table. Multilevel analysis by the municipality code for cancer mortality in Kanagawa, Japan, 2000–2015. S8 Table. Correlation coefficients of community SES indicators by year in Kanagawa, Japan, 2000–2015. S9 Table. Average and SD of land price, neighborhood income, education level, employment rate, morbidity, and mortality for each cancer type in urban, town, and rural areas in Kanagawa, Japan, 2000–2015. S10 Table. Linear regression with SES quartiles, year, and aging rate as explanatory variables and cancer incidence or mortality as response variables. S11 Table. Number of deaths for each type of cancer registered in the vital statistics in Kanagawa, Japan, 2000–2015. S12 Table. Regression coefficients of community SES indicators by Poisson regression using community SES indicator and year as explanatory variables and age-adjusted mortality as the response variable in Kanagawa, Japan, 2000–2015. (ZIP)

In 2023, the lifetime risk of cancer mortality for women in Japan was the highest for **************** cancer, with approximately 2.7 percent. **** cancer followed, with a mortality rate of 2.4 percent.

In 2021, the number of brain tumor cases among children in Japan stood at ***, accounting for the highest number among different cancer types in children. In contrast, the number of Ewing sarcoma cases amounted to **.

Japan JP: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 11.200 NA in 2016. This records a decrease from the previous number of 11.500 NA for 2015. Japan JP: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 12.800 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 15.500 NA in 2000 and a record low of 11.200 NA in 2016. Japan JP: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Cancer Screening Market Outlook

According to our latest research, the global cancer screening market size reached USD 167.3 billion in 2024, driven by rising cancer prevalence and the growing emphasis on early detection. The market is expected to expand at a robust CAGR of 7.8% from 2025 to 2033, reaching a projected value of USD 327.1 billion by the end of the forecast period. This significant growth is propelled by advancements in screening technologies, increasing public awareness, and supportive government initiatives aimed at reducing cancer mortality rates worldwide.

A primary growth factor for the cancer screening market is the surging incidence of various cancer types globally. With lifestyle changes, aging populations, and environmental factors contributing to higher cancer rates, the demand for early and accurate diagnostic tools has never been greater. Governments and healthcare organizations are investing heavily in public health campaigns to promote regular screening, especially for high-risk groups. These initiatives not only drive market expansion but also foster the adoption of advanced screening methods, such as liquid biopsies and molecular diagnostics, which are more sensitive and less invasive than traditional approaches.

Technological innovation is another key driver underpinning the expansion of the cancer screening market. The integration of artificial intelligence, machine learning, and next-generation sequencing into screening protocols has revolutionized the accuracy and efficiency of cancer detection. Imaging modalities such as MRI, CT, and PET scans now offer enhanced resolution and specificity, while laboratory and genetic tests are becoming increasingly affordable and accessible. These technological advancements have enabled early-stage detection, improved patient outcomes, and reduced the overall burden on healthcare systems, further fueling market growth.

Moreover, the increasing focus on personalized medicine and risk stratification is reshaping the cancer screening landscape. Healthcare providers are now tailoring screening programs based on genetic predisposition, family history, and individual risk factors, leading to more targeted and effective interventions. This shift towards precision screening is supported by the proliferation of genetic and molecular diagnostic tests, which can identify patients at higher risk and enable proactive monitoring. As a result, the cancer screening market is witnessing heightened demand from both the general population and specialized high-risk cohorts.

Regionally, North America continues to dominate the cancer screening market, accounting for the largest share due to well-established healthcare infrastructure, high awareness levels, and favorable reimbursement policies. However, the Asia Pacific region is emerging as the fastest-growing market, driven by increasing healthcare investments, rising cancer incidence, and expanding screening programs in countries such as China, India, and Japan. Europe also maintains a significant presence, supported by robust public health initiatives and widespread adoption of advanced screening technologies. These regional trends underscore the global momentum towards early cancer detection and the pivotal role of screening in reducing cancer-related morbidity and mortality.

Test Type Analysis

The cancer screening market is segmented by test type into laboratory tests, imaging tests, genetic tests, endoscopy, and others. Laboratory tests, including blood, urine, and tissue analyses, remain a cornerstone of cancer screening due to their accessibility, cost-effectiveness, and ability to detect a wide range of biomarkers associated with different cancer types. The adoption of liquid biopsies and molecular assays is rapidly increasing, offering non-invasive alternatives with high sensitivity and specificity. These advancements are particularly beneficial for early detection, monitoring disease progression, and guiding treatment decisions, making laboratory tests a critical component of the overall screening ecosystem.

Imaging tests represent another vital segment, encompassing modalities such as mammography, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound. These technologies are indispensable for visualizing tumors, determining their size and location, and assessing the extent of disease spread. The integration of artificial intelligence and machine learning i

Population, aging rate, community SES indicators, cancer incidence, and death due to cancer in Kanagawa, Japan, 2000–2015.

BackgroundGastric cancer remains a significant health burden, particularly in East Asia, where high salt intake is a major risk factor. This study assesses the gastric cancer burden attributable to high salt intake in China, Japan, and South Korea.MethodsWe analyzed data from the GBD 2021 database, including age-standardized mortality rates (ASMR), age-standardized DALY rates (ASDR), and population attributable fraction (PAF) related to high salt intake. The study focused on individuals aged 25 and above, covering global, Chinese, Japanese, and South Korean populations, with trends from 1990 to 2021 and projections through 2042.ResultsFrom 1990 to 2021, the gastric cancer burden attributable to high salt intake significantly decreased globally and in China, Japan, and South Korea. Globally, ASMR decreased from 1.74 per 100,000 in 1990 to 0.89 per 100,000 in 2021 (EAPC = −2.26). In China, ASMR decreased from 3.85 per 100,000 in 1990 to 1.78 per 100,000 in 2021 (EAPC = −2.56), with similar declines in Japan and South Korea. Gender disparities remain, with men bearing a significantly higher gastric cancer burden, especially among the elderly.ConclusionWhile high salt intake’s contribution to gastric cancer decreased from 1990 to 2021, it remains a major factor in mortality and DALYs, particularly among elderly and male populations. However, these findings should be interpreted with caution due to reliance on modeled population-level data and the inability to establish causality from observational sources.

In 2023, the lifetime risk of cancer mortality for men in Japan was highest for **************** cancer, with around 5.9 percent. **************** cancer followed with a lifetime risk of cancer mortality of 3.1 percent.

Proton Therapy Systems Market Outlook

According to our latest research, the Global Proton Therapy Systems market size was valued at $2.1 billion in 2024 and is projected to reach $5.6 billion by 2033, expanding at a robust CAGR of 11.2% during the forecast period of 2024–2033. The primary growth driver for this market is the increasing global prevalence of cancer, coupled with rising demand for advanced, minimally invasive, and highly targeted radiation therapies. Proton therapy, with its precision in targeting tumors while sparing healthy tissues, is gaining traction as a preferred modality, especially for pediatric and complex cancers. This trend is being further fueled by technological advancements in proton therapy systems, growing awareness among healthcare professionals, and supportive policy frameworks that promote the adoption of cutting-edge cancer treatment technologies.

Regional Outlook

North America currently commands the largest share of the global proton therapy systems market, accounting for nearly 42% of total market revenue in 2024. The region’s dominance is attributed to its mature healthcare infrastructure, high adoption rates of advanced medical technologies, and substantial investments in cancer research and treatment facilities. The United States, in particular, leads the charge, with numerous state-of-the-art proton therapy centers and a supportive reimbursement landscape. Favorable government policies, a strong presence of leading medical device manufacturers, and robust funding for oncology research further bolster the market. Additionally, the region’s proactive approach to early cancer diagnosis and the increasing prevalence of cancer cases continue to drive demand for proton therapy systems, positioning North America as the epicenter of innovation and adoption in this sector.

The Asia Pacific region is forecasted to be the fastest-growing market for proton therapy systems, with a projected CAGR exceeding 14.5% during 2024–2033. This rapid growth is underpinned by rising cancer incidence rates across populous countries such as China, India, and Japan, coupled with expanding healthcare budgets and infrastructure development. Governments in the region are increasingly prioritizing cancer care, leading to significant investments in advanced treatment modalities like proton therapy. Japan has emerged as a regional leader, with notable government support and several operational proton therapy centers. Meanwhile, China is witnessing a surge in both public and private investments aimed at establishing new proton therapy facilities. The increasing awareness of the benefits of proton therapy, along with improvements in healthcare accessibility and insurance coverage, are key factors driving the market’s exponential growth in Asia Pacific.

Emerging economies in Latin America and the Middle East & Africa are gradually embracing proton therapy, though at a slower pace due to infrastructural and economic constraints. These regions face challenges such as limited access to capital-intensive medical equipment, insufficient trained personnel, and lack of specialized treatment centers. However, localized demand is steadily rising, particularly in urban centers where cancer prevalence is increasing and private healthcare providers are seeking to differentiate themselves through advanced treatment offerings. Policy reforms aimed at improving healthcare infrastructure, alongside international collaborations and technology transfer agreements, are beginning to facilitate the adoption of proton therapy systems. Despite these positive trends, the market’s growth in emerging economies remains contingent on overcoming barriers related to funding, regulatory approvals, and the establishment of sustainable operational models.

Report Scope

BackgroundColon cancer, esophageal cancer, and stomach cancer are the common causes of morbidity and mortality in China, Japan, the US., and India. The current study aims to assess and compare secular trends of the mortality of gastrointestinal cancers during the period, 1990–2017 in age-specific, time period, and birth cohort effects.MethodWe used the Joinpoint model to collect age-standardized mortality rates (ASMRs) for four countries. We designed an age-period-cohort (APC) analysis to estimate the independent effects on the mortality of three types of cancers.ResultThe Joinpoint model shows that in addition to the death rate of esophageal cancer in Japan, the ASMR of esophageal cancer and stomach cancer in other countries declined rapidly. The APC analysis presented a similar pattern of age effect between four countries for colon cancer and stomach cancer, which increased from 20 to 89 age groups. Differently, the period effect rapidly increased for esophageal cancer and stomach cancer in the US, and the period effect in China presented a declining volatility, showing its highest value in 2007. In future, highest mortality trends are likely to occur in China.ConclusionTherefore, the obvious increase in colon cancer recommended that earlier tactics must be performed to reduce mortality from specific causes from 2018 to 2027.

DNA Methylation Cancer Atlas Panels Market Outlook

According to our latest research, the Global DNA Methylation Cancer Atlas Panels market size was valued at $412 million in 2024 and is projected to reach $1.08 billion by 2033, expanding at a CAGR of 11.3% during 2024–2033. The primary growth driver for this market is the increasing prevalence of cancer worldwide, which is compelling healthcare providers and researchers to adopt advanced epigenetic profiling tools for early diagnosis, prognosis, and personalized treatment strategies. As cancer detection and management move toward precision medicine, the demand for comprehensive methylation panels that enable high-throughput, accurate, and cost-effective analysis of cancer-specific biomarkers is accelerating rapidly. This surge is further amplified by ongoing technological innovations in sequencing and PCR-based platforms, which are continuously improving the sensitivity, specificity, and scalability of DNA methylation analysis.

Regional Outlook

North America currently dominates the DNA Methylation Cancer Atlas Panels market, accounting for the largest share of global revenues, estimated at over 42% in 2024. This leadership is attributed to the region's mature healthcare infrastructure, robust investment in cancer research, and the presence of leading biotechnology companies and academic institutions. The United States, in particular, benefits from favorable reimbursement policies, a high adoption rate of advanced diagnostics, and strong collaboration between public and private sectors. Additionally, the region’s proactive regulatory environment and ongoing government initiatives to advance precision medicine have fostered rapid commercialization of innovative methylation panels. The availability of skilled professionals and high awareness among clinicians and patients further solidify North America's position as the primary hub for DNA methylation-based cancer diagnostics and research.

Asia Pacific is emerging as the fastest-growing region in the DNA Methylation Cancer Atlas Panels market, forecasted to register a remarkable CAGR of 14.2% from 2024 to 2033. The surge in regional demand is driven by increasing cancer incidence rates in populous countries such as China, India, and Japan, coupled with rising healthcare expenditures and government initiatives to modernize diagnostic infrastructure. Significant investments in biomedical research, expanding collaborations with global players, and growing awareness about the benefits of early cancer detection are further propelling market growth in Asia Pacific. Local companies are also actively developing cost-effective and scalable methylation panels tailored to the unique genetic backgrounds of Asian populations, which is fostering broader adoption and market penetration across the region.

In emerging economies across Latin America, the Middle East, and Africa, the adoption of DNA Methylation Cancer Atlas Panels is gaining momentum, albeit at a slower pace compared to developed regions. These markets face unique challenges including limited access to advanced diagnostic technologies, lower healthcare spending, and inadequate reimbursement frameworks. However, increasing public and private sector investments in oncology research, growing partnerships with international diagnostic companies, and a gradual shift toward personalized medicine are creating new opportunities for market expansion. Policy reforms aimed at improving cancer care and the establishment of regional cancer registries are expected to drive incremental demand, although infrastructural constraints and affordability issues remain significant barriers to widespread adoption.

Report Scope

Multi-Cancer Early Detection Tests Market Outlook

According to our latest research, the Global Multi-Cancer Early Detection Tests market size was valued at $2.1 billion in 2024 and is projected to reach $8.7 billion by 2033, expanding at a robust CAGR of 17.2% during the forecast period of 2025–2033. The primary growth catalyst for this market is the rising global burden of cancer, coupled with increasing awareness about the benefits of early detection and the rapid advancement of non-invasive diagnostic technologies. As cancer remains a leading cause of mortality worldwide, healthcare systems and patients are increasingly prioritizing early detection solutions that can identify multiple cancers from a single test, thereby improving survival rates and reducing healthcare costs. The integration of innovative technologies such as next-generation sequencing and liquid biopsy is significantly enhancing the accuracy and accessibility of these tests, further propelling market growth on a global scale.

Regional Outlook

North America currently dominates the Multi-Cancer Early Detection Tests market, accounting for the largest share of the global revenue. This leadership is primarily attributed to the region's mature healthcare infrastructure, high adoption rate of advanced diagnostic technologies, and favorable reimbursement policies. The United States, in particular, is at the forefront, with major investments in research and development, a robust presence of key industry players, and strong regulatory support from agencies such as the FDA. The region's proactive approach to cancer screening, coupled with widespread awareness campaigns and a growing emphasis on preventive healthcare, has resulted in early adoption and widespread utilization of multi-cancer early detection tests. Additionally, collaborations between academic institutions and biotech firms have accelerated innovation, further solidifying North America's position as the market leader.

The Asia Pacific region is projected to be the fastest-growing market for Multi-Cancer Early Detection Tests, with a forecasted CAGR exceeding 20% during 2025–2033. This exceptional growth is driven by a surge in healthcare investments, rising cancer incidence, and increasing government initiatives to improve early cancer diagnosis. Countries such as China, Japan, and India are witnessing a rapid expansion in healthcare infrastructure and a growing middle-class population with greater access to advanced medical technologies. Strategic partnerships with global players and the establishment of local manufacturing units are further enhancing market penetration. Moreover, the region's large and aging population base, combined with heightened awareness about the importance of early detection, is fueling demand for innovative, non-invasive diagnostic solutions.

In emerging economies across Latin America, the Middle East, and Africa, the adoption of Multi-Cancer Early Detection Tests is gradually gaining momentum, albeit at a slower pace due to several challenges. Limited healthcare infrastructure, budget constraints, and a lack of widespread awareness about the advantages of early detection pose significant barriers to market growth in these regions. However, ongoing policy reforms, increasing investments in public health, and growing collaborations with international organizations are expected to create new opportunities for market expansion. Localized demand is also being influenced by the rising prevalence of cancer and the need for cost-effective diagnostic solutions tailored to resource-constrained settings. As governments and non-profit organizations intensify their efforts to improve cancer outcomes, the market in these regions is poised for steady, albeit incremental, growth.

Report Scope

The Asia-Pacific cancer vaccines market is experiencing robust growth, projected to reach $2.34 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 11.55% from 2025 to 2033. This expansion is driven by several key factors. Rising cancer incidence rates across the region, particularly in rapidly developing economies like China and India, fuel the demand for effective preventative and therapeutic vaccines. Furthermore, increasing government initiatives focused on improving healthcare infrastructure and raising public awareness about cancer prevention contribute significantly to market growth. Technological advancements in vaccine development, including the emergence of more targeted and personalized therapies like recombinant and viral vector vaccines, are also major contributors. The market is segmented by technology (recombinant, whole-cell, viral vector/DNA, and others), treatment method (preventive and therapeutic), application (prostate, cervical, and other cancers), and geography (China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific). China and India are expected to be the largest markets within the region due to their substantial populations and expanding healthcare sectors. While the market displays strong growth potential, challenges remain. High research and development costs associated with bringing new cancer vaccines to market, coupled with stringent regulatory approvals, present hurdles for companies. Furthermore, ensuring equitable access to these life-saving vaccines across varying socioeconomic strata within the diverse Asia-Pacific region poses a significant challenge. Despite these restraints, the long-term outlook for the Asia-Pacific cancer vaccines market remains positive, fueled by continuous innovation, growing healthcare expenditure, and a rising understanding of the importance of cancer prevention and treatment. The market’s future trajectory hinges on successful clinical trials, favorable regulatory outcomes, and effective strategies to improve vaccine affordability and accessibility across the diverse populations of the region. Recent developments include: January 2023: Genexine, a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, received Fast Track Designation (FTD) from the Korean Ministry of Food and Drug Safety (MFDS) for GX-188E (tirvalimogene teraplasmid), its first-in-class proprietary therapeutic DNA vaccine. GX-188E has the potential to be a key life-saving drug for the treatment of advanced cervical cancer., September 2022: The Central government of India launched the Indian vaccine against cervical cancer Quadrivalent Human Papillomavirus vaccine (HPV). This vaccine was developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT).. Key drivers for this market are: Growing Burden of Cancer, Emphasis on Early Diagnosis of Cancer; Technological Developments in Cancer Vaccines. Potential restraints include: Growing Burden of Cancer, Emphasis on Early Diagnosis of Cancer; Technological Developments in Cancer Vaccines. Notable trends are: Preventive Vaccines is Expected to Show Better Growth Over the Forecast Period..

Snapshot img

Cancer Registry Software Market Size 2025-2029

The cancer registry software market size is valued to increase USD 121.9 million, at a CAGR of 14% from 2024 to 2029. The growing prevalence of cancer cases will drive the cancer registry software market.

Major Market Trends & Insights

North America dominated the market and accounted for a 51% growth during the forecast period.
By End-user - Government and third party segment was valued at USD 24.20 million in 2023
By Type - Stand-alone software segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: 181.04 million
Market Future Opportunities: USD 121.90 million
CAGR : 14%
North America: Largest market in 2023

Market Summary

The market encompasses a continually evolving landscape shaped by advancements in core technologies and applications, service types, and regulatory frameworks. With the growing prevalence of cancer cases worldwide, the demand for robust and efficient cancer registry software solutions has surged. The growth is fueled by the increasing clinical research for oncology and the need for accurate, standardized data collection and analysis.
However, data privacy and security concerns pose significant challenges, necessitating stringent compliance with regulations such as HIPAA and GDPR. As regional healthcare systems adopt digital transformation, the market is witnessing a proliferation of solutions tailored to specific needs in North America, Europe, and Asia Pacific.

What will be the Size of the Cancer Registry Software Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Cancer Registry Software Market Segmented and what are the key trends of market segmentation?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premises
  Cloud-based


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    Japan


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period.

Cancer registry software plays a pivotal role in assisting government and third-party agencies in managing and analyzing data related to cancer cases. These solutions facilitate the collection, storage, and statistical modeling of oncology data, enabling agencies to monitor cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. Governments utilize cancer registry software to ensure data quality through data validation rules, de-identification, and HIPAA compliance. They also employ data visualization tools, reporting dashboards, and data integration methods to analyze trends and patterns. This data analysis helps identify high-risk populations, geographic disparities, and emerging cancer types.

Moreover, cancer registry software supports population health management and patient data management, ensuring secure data storage, user access control, and audit trails. API integrations enable seamless data exchange with other healthcare systems, facilitating clinical data exchange and follow-up procedures. The future of cancer registry software is promising, with adoption expected to grow significantly. According to recent studies, the number of cancer registries worldwide is projected to increase by 20%, while the use of electronic registries is anticipated to surge by 30%. These trends reflect the ongoing digitization of healthcare and the growing recognition of the value of data-driven insights in improving cancer care and outcomes.

Request Free Sample

The Government and third party segment was valued at USD 24.20 million in 2019 and showed a gradual increase during the forecast period.

Furthermore, cancer registry software supports cancer surveillance, disease registries, and cancer staging, providing valuable data for mortality reporting and treatment protocols. It also facilitates incidence reporting, case ascertainment, and survival analysis, ensuring that governments and third-party agencies have access to the most accurate and up-to-date information for informed decision-making. In conclusion, cancer registry software is a crucial tool for governments and third-party agencies seeking to monitor and improve cancer care. Its features, including

Snapshot img

Brachytherapy Afterloaders Market Size 2024-2028

The brachytherapy afterloaders market size is forecast to increase by USD 62.9 million at a CAGR of 12% between 2023 and 2028.

The market is witnessing significant growth due to the rise in cancer incidence and increasing focus on developing countries. The increasing number of cancer patients worldwide is driving the demand for advanced cancer treatment technologies, including brachytherapy afterloaders. Furthermore, the high cost of these devices is a major challenge for the market, as they are not affordable for all patients. 
However, the market is expected to grow steadily due to the benefits offered by brachytherapy, such as precise radiation delivery and reduced side effects compared to traditional external beam radiation therapy. Additionally, the increasing investment in research and development activities and radiotherapy devices by market players is expected to lead to the launch of more cost-effective and efficient brachytherapy afterloaders, making them accessible to a larger patient population.
In summary, the market for brachytherapy afterloaders is expected to grow steadily due to the increasing incidence of cancer, focus on developing countries, and investment in research and development of medical technologies, despite the high cost being a significant challenge.

What will be the Size of the Brachytherapy Afterloaders Market During the Forecast Period?

Request Free Sample

The market is witnessing significant growth due to the increasing prevalence of cancer and the subsequent demand for advanced radiotherapy treatments. Brachytherapy, a type of radiotherapy, utilizes afterloaders to deliver high-dose-rate (HDR) or low-dose-rate (LDR) radiation directly to the tumor site. This targeted approach reduces radiotherapy side effects, making it an attractive alternative to traditional external beam radiation therapy. Radiation oncology is increasingly adopting brachytherapy for preventive and palliative treatment of various types of cancer, including skin cancer, melanoma, leukemia, lymphoma, and others. The technology's ability to offer personalized radiotherapy planning and precision dosage delivery further enhances its appeal.
However, concerns regarding the complexity and cost of brachytherapy afterloader systems may hinder market growth. Despite these challenges, advancements in radiotherapy technology continue to drive innovation, such as the development of more user-friendly systems and the integration of artificial intelligence for improved treatment planning and delivery. Cancer screening programs and the growing awareness of radiotherapy as an effective cancer treatment modality are expected to fuel the demand for brachytherapy afterloaders In the coming years. Overall, the market is poised for continued growth as the need for effective, targeted cancer treatments increases.

How is this Brachytherapy Afterloaders Industry segmented and which is the largest segment?

The brachytherapy afterloaders industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  HDR afterloaders
  PDR afterloaders


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Product Insights

The hdr afterloaders segment is estimated to witness significant growth during the forecast period.

Brachytherapy, a form of internal radiation therapy, utilizes radioactive sources placed near or inside a tumor for a defined period. High-dose rate (HDR) brachytherapy, delivering more than 12 gray/hour (Gy/h), requires the use of a remote afterloader to transfer the radioactive source through applicators and tubes to the treatment site. HDR brachytherapy is administered in specialized rooms due to the high-dose nature of the procedure. Imaging techniques such as ultrasound, magnetic resonance imaging (MRI), and Power Doppler are used to guide the placement of the radioactive seeds. HDR brachytherapy is commonly used for cancer types like breast and prostate, aiding In the survival of cancer cells.

Cancer therapy centers employ HDR brachytherapy to treat various cancer cases, using advanced technologies like Positron Emission Tomography (PET) and imaging techniques to optimize treatment. The healthcare infrastructure continues to expand, driving the demand for HDR brachytherapy afterloaders.

Get a glance at the Brachytherapy Afterloaders Industry report of share of various segments Request Free Sample

The HDR afterloaders segment was valued at USD 42.60 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to cont

The Asia-Pacific pancreatic cancer therapeutics and diagnostics market is experiencing robust growth, projected to reach a substantial market size driven by increasing prevalence of pancreatic cancer, advancements in diagnostics and therapeutics, and rising healthcare expenditure across the region. The market's 6.40% CAGR from 2019 to 2024 suggests a significant expansion, with this momentum expected to continue through 2033. Key drivers include an aging population, lifestyle changes contributing to increased incidence rates, and greater awareness of the disease. Significant advancements in targeted therapies, such as immunotherapy and precision medicine approaches, are transforming treatment paradigms and contributing to market expansion. The segment dominated by targeted therapies is further propelled by ongoing research and development in this area. While the market faces challenges like high treatment costs and limited access to advanced diagnostic tools in certain regions, particularly in some parts of the Rest of Asia-Pacific, the overall growth trajectory remains positive. The strong presence of major pharmaceutical and medical device companies in the region, coupled with increasing government initiatives to improve cancer care infrastructure, further contributes to this growth. Within the Asia-Pacific region, China, Japan, India, and South Korea represent significant market segments due to their large populations, relatively high cancer rates, and improving healthcare infrastructure. The segment analysis reveals that the combination of surgery, chemotherapy, radiation therapy, and targeted therapy dominates treatment approaches. Advanced diagnostics, including imaging, biopsy, and endoscopy, are playing a crucial role in early detection and accurate diagnosis, driving market growth in the diagnostic segment. Future growth will likely be influenced by the success of ongoing clinical trials for novel therapies, government regulations and reimbursement policies impacting the affordability and accessibility of treatments and diagnostics, and the continued evolution of minimally invasive surgical techniques. The competitive landscape is characterized by established global players and emerging regional companies, fostering innovation and driving competition in the market. Key drivers for this market are: , Increasing Incidence and Prevalence of Pancreatic Cancer; Rising Awareness and Concern about the Disease; Technological Advancements and Innovation of New Products. Potential restraints include: , Increasing Incidence and Prevalence of Pancreatic Cancer; Rising Awareness and Concern about the Disease; Technological Advancements and Innovation of New Products. Notable trends are: Radiotherapy is Expected to register a High CAGR.

Prostate specific antigen (PSA) is widely used as a diagnostic biomarker for prostate cancer (PC). However, due to its low predictive performance, many patients without PC suffer from the harms of unnecessary prostate needle biopsies. The present study aims to evaluate the reproducibility and performance of a genetic risk prediction model in Japanese and estimate its utility as a diagnostic biomarker in a clinical scenario. We created a logistic regression model incorporating 16 SNPs that were significantly associated with PC in a genome-wide association study of Japanese population using 689 cases and 749 male controls. The model was validated by two independent sets of Japanese samples comprising 3,294 cases and 6,281 male controls. The areas under curve (AUC) of the model were 0.679, 0.655, and 0.661 for the samples used to create the model and those used for validation. The AUCs were not significantly altered in samples with PSA 1–10 ng/ml. 24.2% and 9.7% of the patients had odds ratio 2 (high risk) in the model. Assuming the overall positive rate of prostate needle biopsies to be 20%, the positive biopsy rates were 10.7% and 42.4% for the low and high genetic risk groups respectively. Our genetic risk prediction model for PC was highly reproducible, and its predictive performance was not influenced by PSA. The model could have a potential to affect clinical decision when it is applied to patients with gray-zone PSA, which should be confirmed in future clinical studies.